Novartis Ag (NVSEF) Cash & Current Investments (2009 - 2026)

Novartis Ag has disclosed Cash & Current Investments across 14 years of filings, most recently posting $100.0 million for Q1 2026.

• Cash & Current Investments for Q1 2026 came in at $100.0 million, down 23.08% year-over-year; the trailing twelve-month figure through Mar 2026 was $687.0 million (down 52.26% YoY), and the FY2025 annual result was $2.7 billion, up 22.05% from the prior year.
• Cash & Current Investments came in at $100.0 million for Q1 2026 at Novartis Ag, down from $2.7 billion in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $2000.2 billion in Q1 2024 to a low of $70.0 million in Q1 2022.
• The 5-year median for Cash & Current Investments is $2.2 billion (2024), against an average of $122.6 billion.
• Across the five-year window, Cash & Current Investments surged 769217.31% in 2024 and slumped 99.99% in 2025, its largest moves.
• Novartis Ag's Cash & Current Investments stood at $18.9 billion in 2022, then retreated by 23.78% to $14.4 billion in 2023, then plunged by 84.47% to $2.2 billion in 2024, then increased by 22.05% to $2.7 billion in 2025, then plunged by 96.34% to $100.0 million in 2026.
• The last three Cash & Current Investments figures came in at $100.0 million (Q1 2026), $2.7 billion (Q4 2025), and $197.0 million (Q3 2025), per Business Quant data.